Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | DRD3 | P35462 | 8/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 6/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 4/20 | 0.39 |
| ▸ | DRD5 | P21918 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014449 | 0.96 | DRD2 (0.39) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL17014326 | 0.94 | DRD2 (0.39) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL17019663 | 0.91 | DRD2 (0.40) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL17019699 | 0.85 | DRD2 (0.40) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL17014496 | 0.83 | DRD2 (0.37) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL17014405 | 0.83 | DRD2 (0.36) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL17019619 | 0.82 | DRD2 (0.40) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL12600417 | 0.79 | RXRG (0.43) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL17014501 | 0.78 | DRD2 (0.37) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL15746291 | 0.76 | DRD2 (0.32) | DRD2DRD3HTR1DDRD4HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | HAVCR2, SLC10A1, SORD | DRD2 3934/4885DRD3 2599/4885HTR1D 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.